中国癌症杂志 ›› 2021, Vol. 31 ›› Issue (3): 221-226.doi: 10.19401/j.cnki.1007-3639.2021.03.009

• 综述 • 上一篇    下一篇

单细胞测序在三阴性乳腺癌新辅助化疗中的应用研究进展

胡喜娥 1 ,杨振宇 1 ,薛景毅 2 ,杨 平 1 ,彭书甲 1 ,袁利娟 1 ,包国强 1   

  1. 1. 空军军医大学第二附属医院普通外科,陕西 西安 710038 ;
    2. 陕西中医药大学第二临床医学院,陕西 咸阳 712000

  • 出版日期:2021-03-30 发布日期:2021-04-01
  • 通信作者: 包国强 E-mail: guoqiang@fmmu.edu.cn
  • 基金资助:
    国家自然科学基金(81572916)。

Research progress of single-cell sequencing in neoadjuvant chemotherapy for triple-negative breast cancer

HU Xi’e 1 , YANG Zhenyu 1 , XUE Jingyi 2 , YANG Ping 1 , PENG Shujia 1 , YUAN Lijuan 1 , BAO Guoqiang 1   

  1. 1. General Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi’an 710038, Shannxi Province, China; 2. The Second Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang 712000, Shannxi Province, China

  • Online:2021-03-30 Published:2021-04-01
  • Contact: BAO Guoqiang E-mail: guoqiang@fmmu.edu.cn

摘要: 三阴性乳腺癌是最具侵袭性、恶性程度最高的乳腺癌类型,目前多采用以化疗为主的综合治疗方案,新辅助化疗在其中发挥重要作用,但近半数患者会出现耐药,而具体机制尚不明确。单细胞测序技术能够在单个细胞基础上精准评估肿瘤发生、发展过程中基因组、转录组和表观遗传学信息的改变,为明确诊断肿瘤亚型、了解肿瘤耐药机制、发现治疗新靶点、评估疗效与预后等提供有力工具,在三阴性乳腺癌的新辅助化疗中具有广阔的应用前景。

关键词: 三阴性乳腺癌, 单细胞测序, 新辅助化疗, 肿瘤异质性

Abstract: Triple-negative breast cancer is the most invasive and malignant type of breast cancer. At present, therapy for triple-negative breast cancer is the comprehensive treatment regimens based on chemotherapy, in which neoadjuvant chemotherapy plays an important role. However, nearly half of the patients with triple-negative breast cancer are resistant to the treatment, and the specific mechanism is still unclear. Single-cell sequencing is based on accurate assessment of a single cell of tumor, which can evaluate the changes of genome, transcriptome and epigenetic information of tumor in its occurrence and progression. It provides a powerful tool for the diagnosis of tumor subtypes, understanding the mechanism of drug resistance of tumor, finding new therapeutic targets and evaluating efficacy and prognosis, and has a wide application prospect in the neoadjuvant chemotherapy for triple-negative breast cancer.

Key words: Triple-negative breast cancer, Single-cell sequencing, Neoadjuvant chemotherapy, Tumor heterogeneity